BURLINGTON, Mass.--(BUSINESS WIRE)--Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the current dominance of Bristol-Myers Squibb/Gilead’s Atripla in the human immunodeficiency virus (HIV) drug market will be challenged over the next decade by two emerging fixed-dose combination products—Gilead’s Quad and Gilead/Janssen’s Complera (rilpivirine/emtricitabine/tenofovir). Quad, the first integrase inhibitor-based fixed-dose combination to enter the HIV drug market, is forecast to become the market leader by 2020 with more than $3 billion in sales in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
